EA202092296A1 - MOLECULAR ADJUVANT - Google Patents

MOLECULAR ADJUVANT

Info

Publication number
EA202092296A1
EA202092296A1 EA202092296A EA202092296A EA202092296A1 EA 202092296 A1 EA202092296 A1 EA 202092296A1 EA 202092296 A EA202092296 A EA 202092296A EA 202092296 A EA202092296 A EA 202092296A EA 202092296 A1 EA202092296 A1 EA 202092296A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
daa
adc
disease characterized
molecular adjuvant
Prior art date
Application number
EA202092296A
Other languages
Russian (ru)
Inventor
Патрик Хендрикус Корнелис Ван Беркел
Джей Маршалл Фейнголд
Йенс ВЮРТНЕР
Джеймс Адамс
Original Assignee
Адс Терапьютикс Са
Медиммьюн Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Адс Терапьютикс Са, Медиммьюн Лимитед filed Critical Адс Терапьютикс Са
Priority claimed from PCT/EP2019/063262 external-priority patent/WO2019224275A1/en
Publication of EA202092296A1 publication Critical patent/EA202092296A1/en

Links

Abstract

Данное изобретение относится к видам терапии для лечения заболевания, характеризующегося ассоциированным с заболеванием антигеном (DAA); описаны способы вакцинации. В частности, в описании раскрыты молекулярные адъюванты ADC против CD25 для применения в индукции или усилении иммунного ответа субъекта против DAA, что позволяет лечить заболевание, характеризующееся DAA. Также описаны схемы применения для лечения солидных опухолей с помощью ADC. Данное описание относится к лечению патологических состояний, например злокачественное новообразование, с помощью ADC против CD25.This invention relates to therapies for the treatment of a disease characterized by a disease associated antigen (DAA); methods of vaccination are described. In particular, the disclosure discloses molecular adjuvants of anti-CD25 ADC for use in inducing or enhancing a subject's immune response against DAA, which allows the treatment of a disease characterized by DAA. Regimens for the treatment of solid tumors with ADC are also described. This disclosure relates to the treatment of pathological conditions such as cancer with anti-CD25 ADCs.

EA202092296A 2018-11-07 2019-05-22 MOLECULAR ADJUVANT EA202092296A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1818152.9A GB201818152D0 (en) 2018-11-07 2018-11-07 Molecular adjuvant
PCT/EP2019/063262 WO2019224275A1 (en) 2018-05-23 2019-05-22 Molecular adjuvant

Publications (1)

Publication Number Publication Date
EA202092296A1 true EA202092296A1 (en) 2021-05-21

Family

ID=64655555

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202092296A EA202092296A1 (en) 2018-11-07 2019-05-22 MOLECULAR ADJUVANT

Country Status (2)

Country Link
EA (1) EA202092296A1 (en)
GB (1) GB201818152D0 (en)

Also Published As

Publication number Publication date
GB201818152D0 (en) 2018-12-19

Similar Documents

Publication Publication Date Title
PH12020500670A1 (en) Molecular adjuvant
EA201890355A1 (en) NEW METHODS OF IMMUNE RESPONSE INDUCTION
BR112021018694A2 (en) Extracellular vesicles for vaccine delivery
MX2022002504A (en) Antibodies to cd40.
WO2016109546A3 (en) Methods and compositions for prognosis and treatment of cancers
EA201000207A1 (en) NEW IMMUNOGENIC EPITOPES FOR IMMUNOTHERAPY
MX2018010586A (en) Sting activating nanovaccine for immunotherapy.
EA201800148A1 (en) CHALLENGE VACCINE FOR CANCER TREATMENT
TW201613558A (en) Novel vaccine compositions for porcine epidemic diarrhea virus and porcine deltacoronavirus
UY37594A (en) IMMUNE BIOMARCATOR TO PREACH THE CLINICAL EFFECT OF CANCER IMMUNOTHERAPY
EA201491171A1 (en) SUBSTANCES CONTAINING IMPROVED IL-12 GENETIC STRUCTURES, VACCINES, IMMUNOTHERAPEUTIC COMPOSITIONS AND METHODS OF THEIR USE
PH12016502445A1 (en) Antibodies directed against cd127
EA201890747A1 (en) METHODS OF TREATING INFLAMMATORY DISEASES
CY1123275T1 (en) BINDING MOLECULES SPECIFICALLY FOR IL-21 AND USES THEREOF
EA201891601A1 (en) METHODS AND COMPOSITIONS ENHANCED EFFICIENCY BY MEDIATED SUPERANTIGEN IMMUNOTHERAPY OF MALIGNANT TUMORS
EA201291373A1 (en) VACCINE AND METHODS TO ELIMINATE INFECTION CAUSED BY CAMPYLOBACTER
EA202090401A1 (en) ANTI-TIM-3 ANTIBODIES AND THEIR APPLICATION
MX2023001540A (en) Cancer vaccines and methods of treatment using the same.
BRPI0920622A8 (en) African equine disease virus vaccine
CY1122061T1 (en) CHIMERIC SOLUBLE INTERLEUKIN-10 RECEPTOR AND THERAPEUTIC USE THEREOF
EA202092824A1 (en) COMBINATION THERAPY
EA202092296A1 (en) MOLECULAR ADJUVANT
MX2022000263A (en) Novel cancer antigens and methods.
MX2021015765A (en) Novel cancer antigens and methods.
MX2021004453A (en) Novel cancer antigens and methods.